Market Research Logo

Infectious Diseases Market in US 2015-2019

Infectious Diseases Market in US 2015-2019

About Infectious Diseases

Human beings are prone to various kinds of infections. Infectious diseases are caused by various pathogenic microorganisms such as bacteria, fungi, parasites, and viruses. Antimicrobials are used to treat infections. They act by killing or resisting the growth of the microorganisms. They either act via the host defense system or directly target the causative agent. Based on the target organism, antimicrobials can be classified into anti-bacterial, anti-viral, anti-fungal, and anti-parasitic drugs.

Technavio's analysts forecast the infectious diseases market in US to grow at a CAGR of 3.37% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the infectious diseases market in US for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of drugs administered to treat infectious diseases caused by bacteria, viruses, fungi, and parasites.The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the infectious diseases market in US. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

Technavio's report, Infectious Diseases Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. In addition, it discusses the major drivers that influence the growth of the market, challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.

Key Vendors

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Pfizer
Other Prominent Vendors
  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Chimerix Pharmaceuticals
  • Cubist
  • Eli Lilly
  • Isis Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Novartis
  • Sanofi
  • Vertex
Market Driver
  • Rise in patient population
  • For a full, detailed list, view our report
Market Challenge
  • Generic erosion
  • For a full, detailed list, view our report
Market Trend
  • Emergence of IFN-free therapies
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Infectious Diseases Market in the US 2015-2019

Technavio recognizes the following companies as the key players in the infectious diseases market in the US: F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck and Pfizer

Other Prominent Vendors in the market are: AbbVie, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis, Sanofi and Vertex

Commenting on the report, an analyst from Technavio’s team said: “The development and emergence of various all-oral IFN-free regimens are expected to boost market growth during the forecast period. These therapies are projected to achieve a higher SVR and cause fewer side effects than the currently approved therapies.”

According to the report, the increased patient population with hepatitis and HIV propels market growth. The surge in infectious diseases results in the increased consumption of medicines.

Further, the report states that the generic erosion of marketed drugs restricts market growth.

Companies Mentioned

F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, AbbVie, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis, Sanofi, Vertex

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Market Landscape
    • Market Overview
    • Market Size and Forecast
      • Table Infectious Diseases Market in US 2014-2019 ($ millions)
      • Market Penetration
      • Marketing Approvals
      • Patent Protection
      • Regulatory Designation
      • Orphan Drug Designation
      • WHO Recognition
      • Other Factors
    • Five Forces Analysis
  • Epidemiology
    • Viral Infections
    • Fungal Infections
    • Bacterial Infections
    • Parasitic Infections
  • Market Segmentation by Type of Drug
    • Table Segmentation of Infectious Diseases Market in US by Type of Drug
    • Table Segmentation of Infectious Diseases Market in US by Type of Drug 2014
    • Table Segmentation of Infectious Diseases Market in US by Type of Drug 2019
    • Anti-bacterial Drugs
      • Table Types of Anti-bacterial Drug by Chemical Class
      • Anti-bacterial Drugs Market in US
        • Table Anti-bacterial Drugs Market in US 2014-2019 ($ millions)
    • Anti-viral Drugs
      • Table Types of Anti-viral Drug by Disease
      • Anti-viral Drugs Market in US
        • Table Anti-viral Drugs Market in US 2014-2019 ($ millions)
    • Anti-fungal Drugs
      • Table Types of Anti-fungal Drugs by Chemical Class
      • Anti-fungal Drugs Market in US
        • Table Anti-fungal Drugs Market in US 2014-2019 ($ millions)
    • Anti-parasitic Drugs
      • Anti-parasitic Drugs Market in US
        • Table Anti-parasitic Drugs Market in US 2014-2019 ($ millions)
  • Market Segmentation by Route of Administration
    • Table Segmentation of Infectious Diseases Market in US by Route of Administration
    • Oral
    • Parenteral
    • Topical
      • Table Segmentation of Infectious Diseases Market in US by Route of Administration 2014
  • Buying Criteria
  • Market Growth Drivers
  • Drivers and their Impact
  • Market Challenges
  • Impact of Drivers and Challenges
  • Market Trends
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Gilead Sciences
        • Table Gilead Sciences: Revenue of Stribild 2012-2014 ($ millions)
        • Table Gilead Sciences: Revenue of Truvada 2011-2014 ($ millions)
        • Table Gilead Sciences: Revenue of Atripla 2011-2014 ($ millions)
        • Table Gilead Sciences: Revenue of Complera/Eviplera 2011-2014 ($ millions)
        • Table Gilead Sciences: Revenue of Viread 2011-2014 ($ millions)
        • Table Gilead Sciences: Revenue of Hepsera 2011-2013 ($ millions)
        • Table Gilead Sciences: Revenue of AmBisome 2011-2014 ($ millions)
        • Table Gilead Sciences: Percentage Share of Major Anti-infective Drugs 2014
      • Johnson & Johnson
        • Table Johnson & Johnson: YOY Revenue and Growth Rate of Anti-infective Drugs Segment 2011-2014 ($ millions)
        • Table Johnson & Johnson: Revenue of Key Anti-infective Drugs 2011-2014 ($ millions)
      • Merck
        • Table Merck: Key Anti-infective Drugs Portfolio
        • Table Merck: Share of Key Anti-infective Drugs 2014
        • Table Merck: Share of Key Anti-infective Drugs 2011-2014 ($ millions)
        • Table Merck: Sales Comparison of Key Anti-infective Drugs 2011-2014
      • Pfizer
        • Table Pfizer: Key Anti-infective Drugs Portfolio
        • Table Pfizer: Revenue of Key Anti-infective Drugs 2011-2014
        • Table Pfizer: Share of Key Anti-infective Drugs 2011-2014
      • F. Hoffmann-La Roche
        • Table F. Hoffmann-La Roche: Share of Major Anti-infective Drugs 2014
        • Table F. Hoffmann-La Roche: Revenue of Major Anti-infective Drugs 2012-2014 ($ millions)
      • GlaxoSmithKline
        • Table GlaxoSmithKline: Key Anti-viral Drugs Portfolio
        • Table GlaxoSmithKline: Revenue of Key Anti-viral Drugs (Except ViiV Healthcare) 2014
        • Table GlaxoSmithKline: Key Anti-bacterial Drugs Portfolio
        • Table GlaxoSmithKline: Share of Augmentin in Anti-bacterial Drugs Segment 2014
        • Table GlaxoSmithKline: Key Anti-HIV Drugs Portfolio (ViiV Healthcare)
    • Other and Future Prominent Vendors
  • Key Vendor Analysis
    • F. Hoffmann-La Roche Ltd.
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
      • Sales by Geography
        • Table F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
        • Table F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Gilead Sciences
      • Key Facts
      • Business Overview
      • Geographical Segmentation by Revenue 2013
        • Table Gilead Sciences: Geographical Segmentation by Revenue 2013
      • Recent Developments
      • SWOT Analysis
    • GlaxoSmithKline
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2014
        • Table GlaxoSmithKline: Business Segmentation by Revenue 2014
      • Business Segmentation by Revenue 2013 and 2014
        • Table GlaxoSmithKline: Business Segmentation by Revenue 2013 and 2014 ($ billion)
      • Geographical Segmentation by Revenue 2014
        • Table GlaxoSmithKline: Geographical Segmentation by Revenue 2014
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Johnson & Johnson
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2014
        • Table Johnson & Johnson: Business Segmentation by Revenue 2014
      • Business Segmentation by Revenue 2013 and 2014
        • Table Johnson & Johnson: Business Segmentation by Revenue 2013 and 2014 ($ billion)
      • Geographical Segmentation by Revenue 2014
        • Table Johnson & Johnson: Geographical Segmentation by Revenue 2014
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Merck
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Merck: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Merck: Business Segmentation by Revenue 2012 and 2013 ($ billion)
      • Sales by Geography
        • Table Merck: Sales by Geography 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Pfizer
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2014
        • Table Pfizer: Business Segmentation by Revenue 2014
      • Business Segmentation by Revenue 2013 and 2014
        • Table Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billion)
      • Geographical Segmentation by Revenue 2014
        • Table Pfizer: Geographical Segmentation by Revenue 2014
      • Business Strategy
      • Key Developments
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report